---
layout: post
title: "POTENSI LUMBROKINASE DENGAN CARRIER N,N,N-TRIMETIL KITOSAN KLORIDA (TMC) MENGGUNAKAN LIGAND C-RGD SEBAGAI AGEN FIBRINOLITIK DAN ANTI-PLATELET TERBARUKAN"
author: "Naufal Nandita Firsty, Muhammad Furqan, Ilman Arif Aritonang"
description: "Pendahuluan Trombosis vena merupakan penyakit kardiovaskular nomor 3 terbanyak di dunia Pemberian agen fibrinolitik seperti streptokinase merupakan terapi pilihan pada"
categories: essential
canonical_url: https://jurnal.harianregional.com/essential/id-58611
comments: true
citation_abstract_html_url: "https://jurnal.harianregional.com/essential/id-58611"
citation_pdf_url: "https://jurnal.harianregional.com/essential/full-58611"
tags:

---

## Authors:
Naufal Nandita Firsty, Muhammad Furqan, Ilman Arif Aritonang

## Abstract:
"Pendahuluan: Trombosis vena merupakan penyakit kardiovaskular nomor 3 terbanyak di dunia. Pemberian agen fibrinolitik seperti streptokinase merupakan terapi pilihan pada penyakit tersebut. Namun, kekurangannya yaitu waktu paruhnya yang pendek, tidak spesifik terhadap fibrin, penargetan yang buruk, harganya yang mahal, dan mudah menyebabkan perdarahan. Oleh karena itu diperlukan agen fibrinolitik yang dapat mengatasi beberapa kekurangan dan efek samping agen fibrinolitik saat ini. Literature review ini bertujuan untuk menjelaskan potensi lumbrokinase dengan carrier TMC dan ligand c-RGD sebagai agen fibrinolitik dan antiplatelet terbarukan. Metode yang digunakan dalam penyusunan literature review ini adalah studi pustaka dengan menggunakan jurnal 10 tahun terakhir yang diperoleh dari mesin pencarian seperti Sciencedirect, PubMed, Google Scholar dan ClinicalKey. Pembahasan: Lumbrokinase merupakan enzim hasil ekstraksi dari saluran cerna cacing tanah yang terdiri dari beberapa isoenzim protease serin. Lumbrokinase mempunyai fungsi utama sebagai agen fibrinolitik dengan 2 mekanisme kerja yaitu berperan menghidrolisis fibrin dan fibrinogen serta mengaktifkan plasminogen menjadi plasmin. Selain itu, lumbrokinase juga memiliki efek antiplatelet seperti aspirin. Penggunaan TMC sebagai carrier dapat meningkatkan bioavailabilitas lumbrokinase. Sementara itu, penambahan ligand c-RGD dapat meningkatkan spesifitas terhadap reseptor GPIIb/IIIa yang mencegah fibrinogen berikatan dengan reseptor tersebut sehingga menghambat pembentukan trombus. Simpulan: Dari berbagai penelitian secara in vitro dan in vivo disimpulkan bahwa lumbrokinase dengan carrier TMC dan ligand c-RGD dapat mempercepat trombolisis, dan mengurangi risiko perdarahan sehingga berpotensi sebagai agen fibrinolitik dan antiplatelet terbarukan. Namun, diperlukan penelitian lebih lanjut mengenai dosis terapi, efek samping, dan studi toksisitas."

### Keywords
*Keyword Not Available*

### Downloads:
Download data is not yet available.

{% include adsense.html %}
## References
- 1.	Shi A, Tao Z, Wei P, Zhao J. Epidemiological aspects of heart diseases (Review). Exp Ther Med. 2016;12(3):1645–50.
- 2.	World Health Organization. 2016. Cardiovascular diseases (CVDs)[Internet]. Available from: https://www.who.int/news-room/fact sheets/detail/cardiovascular-diseases-(cvds)
- 3.	Siddiqui T, Dikshit D. Platelets and atherothrombosis: causes, targets and treatments for thrombosis. Current medicinal chemistry. 2013;20(22):2779
- 4.	Kesieme, Kesieme. Deep vein thrombosis: a clinical review. J Blood Med [Internet]. 2011;59.
- 5.	Andriani R, Wahid I. Defisiensi Protein S pada Trombosis Vena Dalam. J Kesehatan Andalas. 2018;7(Supplement 4):100–3.
- 6.	Najihah.Penggunaan Compression Stocking Terhadap Pencegahan Deep Venous(DVT): Literatur Review. Journal of Islamic nursing. 2017;1(1): 0–4.
- 7.	Ali MR, Salim Hossain M, Islam MA, Saiful Islam Arman M, Sarwar Raju G, Dasgupta P, et al. Aspect of thrombolytic therapy: A review. Sci World J. 2014;2014(1).
- 8.	Darotin R, Nurdiana, Nasution TH. Analisis Faktor Prediktor Mortalitas Stroke Hemoragik di Rumah Sakit Daerah dr.Soebandi Jember. Nurseline J. 2017;2(1):1–10.
- 9.	Center for Disease Control and Prevention. 2019.Data and Statistics on Venous Thromboembolism [Internet]. Available from : https://www.cdc.gov/ncbddd/dvt/data.html
- 10.	European Thrombosis & Haemostasis Alliance. European Thrombosis & Haemostasis Alliance Consensus Statement. 2018;1-2.
- 11.	Tambunan KL, Hutagalung EU, Sukrisman L, Saleh I, Gunawan SB, Sofyanuddin S, et al. Venous thromboembolism in 13 Indonesian patients undergoing major orthopedic surgery. Med J Indones. 2009;18(4):249.
- 12.	Absar S, Nahar K, Kwon YM, et al. Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy.Pharmaceutical research. 2013;30(6):1663-1676.
- 13.	Kim J-Y, Kim J-K, Park J-S, et al. The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials. 2009;30(29):5751-5756.
- 14.	Gayatri A, Purwantyastuti. Penggunaan Lumbrokinase sebagai Fibrinolitik dan Antitrombotik Oral. 2013;40(3):167–70.
- 15.	Jin M, Jin G, Huang WEI, Gao Z. PEGylation of Lumbrokinase improves pharmacokinetic profile and enhances anti ‑ thrombotic effect in a rat carotid artery thrombosis model. 2017;4909–14.
- 16.	Jin M, Chen W, Huang W, et al. Preparation of pegylated lumbrokinase and an evaluation of its thrombolytic activity both in vitro and in vivo. Acta Pharmaceutica Sinica B. 2013;3(2):123-129.
- 17.	Quiñones JP, Peniche H, Peniche C. Chitosan based self-assembled nanoparticles in drug delivery. Polymers (Basel). 2018;10(3):1–32.
- 18.	Bernkop-Schnürch A, Dünnhaupt S. Chitosan-based drug delivery systems. Eur J Pharm Biopharm. 2012;81(3):463–9.
- 19.	Liao J, Ren X, Yang B, Li H, Zhang Y, Yin Z. Targeted thrombolysis by using c-RGD-modified N,N,N-Trimethyl Chitosan nanoparticles loaded with lumbrokinase. Drug Dev Ind Pharm [Internet]. 2019;45(1):88–95. Available from: http://dx.doi.org/10.1080/03639045.2018.1522324
- 20.	Srinivasan R, Marchant RE, Gupta AS. In vitro and in vivo platelet targetting by cyclic RGD - Modified liposomes. Journal of biomedical materials research Part A. 2010;93(3):1004-1015.
- 21.	Verma MK, Pulicherla KK. Lumbrokinase - a potent and stable fibrin-specific plasminogen activator. Int J Bio-Science Bio-Technology. 2011;3(2):57–70.
- 22.	Wang KY, Tull L, Cooper E, Wang N, Liu D. Recombinant Protein Production of Earthworm Lumbrokinase for Potential Antithrombotic Application. Evidence-Based Complement Altern Med. 2013;2013:1–8.
- 23.	Xu Z rong, Yang Y mei, Gui Q feng, Zhang L na, Hu L. Expression, purification, and characterization of recombinant lumbrokinase PI239 in Escherichia coli. Protein Expr Purif [Internet]. 2010;69(2):198–203. Available from: http://dx.doi.org/10.1016/j.pep.2009.08.013
- 24.	Antonino RSCMDQ, Fook BRPL, Lima VADO, Rached RÍDF, Lima EPN, Lima RJDS, et al. Preparation and characterization of chitosan obtained from shells of shrimp (Litopenaeus vannamei Boone). Mar Drugs. 2017;15(5):1–12.
- 25.	Younes I, Rinaudo M. Chitin and chitosan preparation from marine sources. Structure, properties and applications. Mar Drugs. 2015;13(3):1133–74.
- 26.	Ways TMM, Lau WM, Khutoryanskiy V V. Chitosan and its derivatives for application in mucoadhesive drug delivery systems. Polymers (Basel). 2018;10(3).
- 27.	Chen G, Svirskis D, Lu W, Ying M, Huang Y, Wen J. N-trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N-trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer. J Control Release [Internet]. 2018;277(March):142–53. Available from: https://doi.org/10.1016/j.jconrel.2018.03.013
- 28.	Xu J, Xu B, Shou D, Xia X, Hu Y. Preparation and evaluation of vancomycin-loaded N-trimethyl chitosan nanoparticles. Polymers (Basel). 2015;7(9):1850–70.
- 29.	Abdassah M. Nanopartikel Dengan Gelasi Ionik. Farmaka. 2012;15(1):45–52
- 30.	Ilinskaya AN, Dobrovolskaia MA. Nanoparticles and the blood coagulation system. Part I: benefits of nanotechnology. Nanomedicine. 2013;8(5):773-784.
- 31.	Pan Y, Wang X, Yin Z. Synthesis and evaluation of cationic polymeric micelles as carriers of lumbrokinase for targeted thrombolysis. Asian J Pharm Sci [Internet]. 2019;14(2):144–53. Available from: https://doi.org/10.1016/j.ajps.2018.03.004

### PDF:

{% include adsense1.html %}

<https://jurnal.harianregional.com/essential/full-58611>

{% include adsense2.html %}

### Published
2021-08-01

### How To Cite
FIRSTY, Naufal Nandita; FURQAN, Muhammad; ARITONANG, Ilman Arif.  POTENSI LUMBROKINASE DENGAN CARRIER N,N,N-TRIMETIL KITOSAN KLORIDA (TMC) MENGGUNAKAN LIGAND C-RGD SEBAGAI AGEN FIBRINOLITIK DAN ANTI-PLATELET TERBARUKAN.Essential: Essence of Scientific Medical Journal, [S.l.], v. 19, n. 1, p. 27-33, aug. 2021. ISSN 2655-6472. Available at: <https://jurnal.harianregional.com/essential/id-58611>. Date accessed: {{ site.time | date: "%d %b. %Y" }}.

## Citation Format
ABNT, APA, BibTeX, CBE, EndNote - EndNote format (Macintosh & Windows), MLA, ProCite - RIS format (Macintosh & Windows), RefWorks, Reference Manager - RIS format (Windows only), Turabian

### Issue
Vol 19 No 1 (2021): Volume 19 No. 1 (Januari - Juni 2021) Essential: Essence of Scientific Medical Journal

### Section 
**Articles**

### Copyright 
{% include inarticle.html %}
<a href="http://creativecommons.org/licenses/by/4.0/" rel="license"><img src="https://i.creativecommons.org/l/by/4.0/88x31.png" alt="Creative Commons License" /></a>
This work is licensed under a <a href="http://creativecommons.org/licenses/by/4.0/" rel="nofollow">Creative Commons Attribution 4.0 International License</a>

{% include multiplex.html %}
